Abstract
4524 Background: To investigate the effect of body mass index (BMI) and body surface area (BSA) on treatment outcome in patients treated with VEGF targeted therapy for metastatic RCC (mRCC). Methods: Baseline characteristics and outcomes on 475 patients (pts) treated with first-line anti-VEGF therapy for mRCC were available from three US and three Canadian Cancer Centers to study the impact of BMI and BSA on survival. Results: Median follow up for the whole cohort was 28 months (mos). Median time to progression (TTP) on targeted therapy was 9.6 mos and median overall survival (mOS) was 24.3 mos. Sunitinib was used in 289 pts (61%), sorafenib in 141 pts (30%) and bevacizumab in 45 pts (9%). At therapy initiation, 141 (30%) pts were considered underweight/normal weight (BMI 30 kg/m2). Using Mosteller formula, 107 (23%) pts had low BSA. On univariable analysis, obese pts had a mOS of 32.5 mos vs. 20.6 mos in non-obese pts (p=0.0001). ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
